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I would like to comment on the recently (October 2016 issue of
Gynecologic Oncology) published guideline for neoadjuvant chemo-
therapy (NACT) in newly diagnosed ovarian cancer and speciﬁcally
with regards to potentially resectable disease (Recommendation 3.1)
(Wright et al., 2016). The decision to proceedwithNACTor primary sur-
gery (PCS) in newly diagnosed stage IIIC disease should not be confused
with the decision of whether surgery is at all appropriate in a given pa-
tient because of her general condition or comorbidities. This should be
clariﬁedﬁrst and be distinct from thedecision of timing of cytoreductive
surgery. The appropriateness of surgery may of course be modiﬁed if
there is a progression during NACT (as Recommendation 7 of the guide-
line advocates) or conversely if an unexpected improvement of the clin-
ical condition of the patient is obtained during palliative chemotherapy.
Availability of the NACT option should not be an “excuse” for not oper-
ating on a potentially resectable patient because of other comorbidities
that would increase her surgical complication risk or because of con-
cerns of inexperienced surgeons that a primary debulking surgery
would be more difﬁcult. Instead the general status of the patient should
weight in the decision of proceeding with NACT only if it is believed to
be related to the burden of the cancer and patients that are expected
to be technically more difﬁcult should be referred to more experienced
centers.
In the case of surgery deemed appropriate the main factor that
should be considered in the decision for the timing of surgery and tip
the balance towards or away from PCS is the stage and bulk of the dis-
ease. Patients who could be considered for NACT are those that meet
the criteria used in the EORTC/NCIC trial (FIGO IIIC and IV) (Vergote et
al., 2010) except for patients in the lower range of FIGO IIIC staging
(major tumormasses of 2–5 cm) as these patients appear to have better
outcomes with PCS (van Meurs et al., 2013). It is noteworthy that in
both trials of PCS versus NACT, that have survival data available at pres-
ent, the complete response rate is more than double in the NACT arm,
nevertheless survival outcomes are similar (Vergote et al., 2010;
Kehoe et al., 2015). On the other hand the bulk of residual disease
after primary surgery is known to be the best predictor of survival out-
comes (Bristow et al., 2002). This may imply that microscopic residual
disease post-NACT is more extensive and difﬁcult to visually identify
thanmicroscopic disease at presentation (Hynninen et al., 2013). A pos-
sible cause of this could be that chemotherapy is able to kill the bulk of
cells in the diffuse peritoneal nodules but stem or tumor initiating cells
resistant to treatment remain and repopulate the tumors (Chang, 2016).
In other tumor types such as triple negative breast cancers where neo-
adjuvant chemotherapy is used and tumors respond well, radiopaque
coils are placed pre-NACT to guide excision of the residual if macroscop-
ically invisible (Pinder et al., 2015). This is obviously impractical inhttp://dx.doi.org/10.1016/j.gore.2016.11.005
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NACT in these tumors. Thus, both available data and theoretical consid-
erations support primary radical surgery over NACT in patients with po-
tentially resectable stage IIIC and certainly those stage IIIC patients with
smaller tumormasses of less than 5 cm inmajor diameter. NACT should
remain a second best option in these patients and should be reserved as
ﬁrst option for patients with stage IV disease, patients with a high risk
for perioperative complications clearly due to tumor-related factors
(where reducing tumor loadmay improve surgical risks), or for patients
that are unlikely to receive optimal cytoreduction even with a meticu-
lous surgical effort. Both PCS and especially NACT will beneﬁt from bet-
ter methods for identiﬁcation of microscopic disease in the future
(Cocco et al., 2015).
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